๐ฐ Compugen Ltd News
Page 2 - Compugen Ltd News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Compugen Ltd. Real-time updates on events, politics, business and more.
February 20, 2024
HOLON, Israel, Feb. 20. 2024 /PRNewswire/ -- Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will...
February 15, 2024
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024. Michelle will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities effective February 29, 2024, after 6 years with Compugen.
February 4, 2024
StockNews.com cut shares of Compugen (NASDAQ:CGEN – Free Report) from a hold rating to a sell rating in a research note released on Thursday. Separately, Stifel Nicolaus upped their price objective on shares of Compugen from $3.00 to $4.00 and gave the company a buy rating in a report on Tuesday, December 19th. Two analysts […]
February 4, 2024
Compugen Ltd. (NASDAQ:CGEN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the five analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year target […]
January 8, 2024
Cancer immunotherapy company Compugen Ltd. (CGEN) announced Monday that Compugen is entitled to receive a $10 million milestone payment from British drug major AstraZeneca (AZN), after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig.
January 8, 2024
Compugen Ltd. (NASDAQ:CGEN – Get Free Report) has received an average rating of “Moderate Buy” from the five brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12 month price […]
January 8, 2024
HOLON, Israel, Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced todayย that on January 4, 2024,...
December 20, 2023
-- Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index adding 0.4% and the Health Care Select Sector SPDR Fund up 0.5%. The iShares Biotechnology ETF rose 1.4%. In...
December 20, 2023
Compugen Ltd. has entered another collaboration, this time exclusively licensing a preclinical antibody program against an IL-18 binding protein with Gilead Sciences Inc. Compugen will handle ongoing preclinical development and a phase I study of COM-503 to treat tumors, then Gilead receives to sole right to further continue developing the asset. Compugen is getting an up-front $60 million and is eligible for a $30 million milestone payment should the IND clear in 2024. Compugen also is eligible...
December 20, 2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon, Israel, to exclusively license its potential first-in-class, pre-clinical antibody ...